Latest Commercial Revenue News

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

Jade Gas Holdings has achieved continuous gas flow from two production wells and secured its first LNG sales agreement with Mongolia’s largest natural gas importer, UB Metan LLC. The company also raised $5 million to support its commercial operations.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

Artrya Limited has secured FDA clearance for its Salix Coronary Plaque module and raised $80 million to fuel its U.S. commercial expansion, marking a pivotal step in its transition from development to revenue generation.

Jade Gas Holdings Limited (ASX – JGH) has launched a $2.1 million Share Purchase Plan offering eligible shareholders new shares at a 12.5% discount, aiming to accelerate commercial gas production and LNG facility development.

Jade Gas Holdings has raised A$5 million through a placement to advance commercial gas production at its Red Lake field, with a follow-up Share Purchase Plan aiming to raise an additional A$2.1 million.

Skin Elements Limited has locked in $2.5 million through a two-tranche placement to accelerate the commercial rollout of its SE Formula biotechnology products, offering investors discounted shares and options.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Centuria Capital Group reported a robust FY25 with $19.7 billion in assets under management and earnings per stapled security exceeding guidance. The group is poised for strong FY26 growth, driven by stabilizing real estate markets and its pioneering sovereign AI Factory.

Cleo Diagnostics has launched a health economic study in partnership with EntityRisk and Norstella to support the U.S. market entry of its Ovarian Cancer Pre-Surgical Test, aiming to refine reimbursement strategies and accelerate commercialisation.

Temple & Webster Group Ltd has reported record FY25 results with revenue climbing 20.7% to $600.7 million and profit before tax more than doubling to $14.8 million, driven by market share gains and disciplined cost management.